{"entity":{"type":"insider","cik":"0001615991","url":"/insider/0001615991","json_url":"/insider/0001615991.json","name":"Polaris Entrepreneurs' Fund VII, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":6,"first":"2016-07-07","last":"2025-09-11","span_basis":"filed_date"},"name_variants":[{"name":"Polaris Entrepreneurs' Fund VII, L.P.","source":"filing","n_filings":6,"first_seen":"2016-07-07","last_seen":"2025-09-11"}],"transactions":[{"id":4456090,"accession":"0001193125-25-201392","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-201392","line_url":"/filing/0001193125-25-201392","is_derivative":false,"issuer_cik":"0001295675","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001295675","owner_cik":null,"owner_name":"Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY W","owner_display_name":"Chee Brian","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1307189.0,"shares_display":"1,307,189","price_per_share":1.53,"price_display":"1.53","price_state":"stated","total_value":1999999.17,"total_display":"1,999,999.17","total_whole":"1,999,999","shares_owned_after":2825500.0,"shares_owned_after_display":"2,825,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-11","scope":"insider","n_lines":2},{"id":9213061,"accession":"0000950170-24-116360","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-116360","line_url":"/filing/0000950170-24-116360#line-1","is_derivative":false,"issuer_cik":"0001295675","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001295675","owner_cik":null,"owner_name":"Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY W","owner_display_name":"Chee Brian","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":909090.0,"shares_owned_after_display":"909,090","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-22","scope":"insider"},{"id":2210008,"accession":"0000950170-24-114788","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-114788","line_url":"/filing/0000950170-24-114788#line-5","is_derivative":false,"issuer_cik":"0001438226","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001438226","owner_cik":null,"owner_name":"Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY W","owner_display_name":"Polaris Entrepreneurs' Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":909090.0,"shares_owned_after_display":"909,090","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-15","scope":"insider"},{"id":3033460,"accession":"0000899243-20-030317","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-030317","line_url":"/filing/0000899243-20-030317","is_derivative":false,"issuer_cik":"0001604477","issuer_name":"SQZ Biotechnologies Co","issuer_ticker":"SQZ","issuer_name_source":null,"issuer_url":"/issuer/0001604477","owner_cik":null,"owner_name":"Polaris Entrepreneurs' Fund VII, L.P.; Polaris Partners VII, L.P.; Polaris Management Co. VII, L.L.C.","owner_display_name":"Polaris Entrepreneurs' Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":2549306.0,"shares_owned_after_display":"2,549,306","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-03","filed_date":"2020-11-03","scope":"insider","n_lines":2},{"id":2344368,"accession":"0001209191-20-051505","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-20-051505","line_url":"/filing/0001209191-20-051505","is_derivative":false,"issuer_cik":"0001611189","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001611189","owner_cik":null,"owner_name":"Polaris Management Co. VII, L.L.C.; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Partners VII, L.P.","owner_display_name":"Polaris Management Co. VII, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":230000.0,"shares_display":"230,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":2990000.0,"total_display":"2,990,000.00","total_whole":"2,990,000","shares_owned_after":214962.0,"shares_owned_after_display":"214,962","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider","n_lines":2},{"id":2144687,"accession":"0001104659-16-131584","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-16-131584","line_url":"/filing/0001104659-16-131584","is_derivative":false,"issuer_cik":"0001556263","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001556263","owner_cik":null,"owner_name":"Polaris Management Co. VII, L.L.C.; Polaris Partners VII, L.P.; Polaris Entrepreneurs' Fund VII, L.P.","owner_display_name":"Polaris Management Co. VII, L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1538333.0,"shares_owned_after_display":"1,538,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-07","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001736730","name":"Camp4 Therapeutics Corp","url":"/issuer/0001736730","role":"Ten percent owner","n_filings":3,"first_seen":"2024-10-15","last_seen":"2025-09-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001604477","name":"SQZ Biotechnologies Co","url":"/issuer/0001604477","role":"Ten percent owner","n_filings":1,"first_seen":"2020-11-03","last_seen":"2020-11-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Ten percent owner","n_filings":1,"first_seen":"2020-09-22","last_seen":"2020-09-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":1,"first_seen":"2016-07-07","last_seen":"2016-07-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001615991","retrieved_at":"2026-08-23T19:41:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}